Virax Biolabs (VRAX)

• Market cap: $2.55M
• 1 day: 0.98%
• 5 days: -13.32%
• 1 month: -11.47%
• 3 months: -37.96%
• 6 months: -50.91%
• Year to date: -82.36%
• 1 year: -79.38%
• 5 years: -99.79%
• 10 years: -99.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.

Employees: 19